01 Industry overview
The pharmacuetical industry at a glance
The global prescription pharmaceutical market was worth approximately $1.53 trillion in 2024, with North America accounting for 54.8% of sales and continued growth driven by specialty medicines, biologics and emerging markets.
- $1.53T[100]
- Global sales, 2024
- 5.5–6.5%[21]
- Forecast CAGR, 2024–2029
- 54.8%[100]
- North America share, 2024
- 46[60]
- Novel drugs approved, 2025
- Market size
- The global prescription pharmaceutical market reached an estimated €1.414 trillion, or $1.529 trillion, at ex-factory prices in 2024. A separate Crisil Intelligence estimate placed the broader global pharmaceutical market at $1.583 trillion in 2024.[100][21]
- Forecast & CAGR
- Crisil Intelligence forecasts the global pharmaceutical market to reach $2.1–$2.2 trillion by 2029, implying a 5.5–6.5% CAGR from 2024 to 2029. Growth is expected to reflect volume expansion in emerging markets and new-product launches in developed markets.[21]
- Market share & regions
- North America represented 54.8% of the global prescription market in 2024, followed by Europe at 22.7%, China at 7.1% and Japan at 4.0%. In Crisil Intelligence’s broader market estimate, North America held 45% and Europe approximately 26% in 2024, reflecting differences in market definitions.[100][21]
- Segmentation
- The 2025 U.S. regulatory pipeline included 34 new molecular entities and 12 biologics among 46 novel CDER approvals. Half of these novel approvals—23 products—received orphan-drug designation, highlighting the importance of specialty and rare-disease medicines.[60]
- Key players & concentration
- The industry is geographically concentrated: North America and Europe together accounted for 77.5% of global prescription pharmaceutical sales in 2024. In pharmaceutical M&A markets, concentration increased by an average of 5.9% during the 12 months following a transaction, according to a U.S. government-commissioned study covering 2010–2023.[100][23]
- Pricing
- In 2022, U.S. prescription-drug prices across brands and generics were 2.78 times those in 33 OECD comparison countries. U.S. brand-name prices were 4.22 times comparison-country prices, while unbranded generic prices were lower at 67% of comparison-country levels.[24][101]
- Trends, drivers & challenges
- Growth is being supported by emerging-market access, new product launches and specialty therapies, while the sector faces patent expiries, geopolitical supply-chain risks and a projected global growth gap of $100 billion by 2028 according to EY. EU pharmaceutical exports supported 926,000 jobs in 2023, but the sector’s value added was exposed to potential trade disruptions worth €43.2 billion with the United States and €14.7 billion with China.[21][25][102]
- Consumer behavior & competition
- The United States accounted for approximately 50% of worldwide prescription-drug sales revenue but only 13% of volume in 2022 across the markets covered by IQVIA MIDAS. Unbranded generics represented 90% of U.S. prescription volume, compared with 41% in the 33 comparison countries.[24]
- M&A
- Global life-sciences M&A investment reached $240 billion in 2025, up 81% from $130 billion in 2024, according to EY. A separate IQVIA review reported that the total number of publicly disclosed life-sciences deals fell 12% year over year in 2025, indicating a market increasingly driven by fewer, larger transactions.[25]
- Regulation
- CDER approved 46 novel drugs in 2025, including 34 new molecular entities and 12 biologics, and approved 18 biosimilars. Of the novel drugs, 23 received orphan-drug designation and 32 were approved in the United States before approval in other countries.[60]
- Latest news
- The latest full-year industry data show a sharp rebound in life-sciences M&A investment in 2025, reaching $240 billion, while FDA reported 46 novel drug approvals for the same year. Current industry outlooks emphasize pipeline replacement, AI-enabled discovery, China-related innovation and specialty medicines as major strategic priorities for 2026.[25][60]
02 Ranking
Top 10 Companies in the Pharmacuetical Industry
The leading companies in the pharmacuetical industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 10, 2026 · Next review December 10, 2026
Verdict
Eli Lilly and Company leads Gitnux's 2026 pharmacuetical ranking with an Overall score of 9.7, with revenue growth 44.7%, operating margin 40.4%, and R&D 20.5% of revenue. Roche is the highest-ranked pharmaceutical and diagnostics company at 9.1, with R&D at 19.8% of revenue and revenue growth 7%.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in prescription medicines
Eli Lilly and Company
US
Ranked #1 · 9.7 · Prescription medicines
Why we picked it: Its prescription medicines and biologics profile includes Mounjaro and Zepbound.
Leader in pharmaceuticals and diagnostics
Roche
CH
Ranked #2 · 9.1 · Pharmaceuticals and diagnostics
Why we picked it: Its pharmaceuticals and diagnostics mix concentrates on oncology and serious diseases.
#3 overall
Novartis
CH
Ranked #3 · 8.9 · Prescription medicines
Why we picked it: It focuses on high-value medicines in cardiovascular, immunology, neuroscience, and oncology.
Pick 1 is the #1 company overall. Pick 2 is the highest-ranked company in the top 5 that adds a new segment; no further segment places in the top 5, so pick 3 follows rank.
Full ranking
Sort by
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Eli Lilly and Company Prescription medicines · US | 9.7 | 9.3 | 9.9 | 9.9 | 9.9 | |
Company snapshot · Eli Lilly and Company · Data as of November 10, 2026 Mounjaro and Zepbound became two of the world's leading prescription medicines by revenue.[103]
| |||||||
| 2 | Roche Pharmaceuticals and diagnostics · CH | 9.1 | 9.7 | 7.9 | 8.8 | 9.9 | |
Company snapshot · Roche · Data as of November 10, 2026 Roche combines pharmaceuticals with diagnostics and focuses heavily on oncology and other serious diseases.[104]
| |||||||
| 3 | Novartis Prescription medicines · CH | 8.9 | 9.4 | 8.8 | 8.4 | 9.0 | |
Company snapshot · Novartis · Data as of November 10, 2026 Novartis focuses on high-value medicines in cardiovascular, immunology, neuroscience and oncology.[30]
| |||||||
| 4 | Novo Nordisk Prescription medicines · DK | 8.9 | 9.3 | 8.7 | 8.0 | 9.9 | |
Company snapshot · Novo Nordisk · Data as of November 10, 2026 Novo Nordisk reached 45.6 million people living with obesity and diabetes in 2025.[105]
| |||||||
| 5 | Johnson & Johnson Prescription medicines · US | 8.9 | 9.9 | 7.8 | 8.3 | 9.0 | |
Company snapshot · Johnson & Johnson · Data as of November 10, 2026 Its Innovative Medicine segment develops and sells prescription medicines across major therapeutic areas.[106]
| |||||||
| 6 | AstraZeneca Innovative prescription medicines · GB | 8.9 | 9.4 | 8.5 | 8.5 | 9.0 | |
Company snapshot · AstraZeneca · Data as of November 10, 2026 AstraZeneca reported 16 blockbuster medicines and medicines impacting more than 100 million lives annually.[76]
| |||||||
| 7 | Sanofi Medicines and vaccines · FR | 8.6 | 9.3 | 8.7 | 8.9 | 7.0 | |
Company snapshot · Sanofi · Data as of November 10, 2026 Sanofi's 2025 sales included major contributions from Dupixent, vaccines and new medicines.[67]
| |||||||
| 8 | Merck Prescription medicines and vaccines · US | 8.5 | 9.4 | 8.3 | 7.0 | 9.0 | |
Company snapshot · Merck · Data as of November 10, 2026 Merck develops and markets prescription medicines, vaccines and biologic therapies worldwide.[107]
| |||||||
| 9 | Pfizer Medicines and vaccines · US | 8.3 | 9.4 | 7.9 | 7.3 | 8.2 | |
Company snapshot · Pfizer · Data as of November 10, 2026 Pfizer discovers, develops, manufactures and sells biopharmaceutical products worldwide.[108]
| |||||||
| 10 | Amgen Biologic and specialty medicines · US | 8.1 | 7.0 | 8.6 | 8.5 | 9.0 | |
Company snapshot · Amgen · Data as of November 10, 2026 Amgen serves approximately 17 million patients globally with a portfolio of biologic medicines.[109]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 10, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 10). Top 10 companies in the pharmacuetical industry. In Pharmacuetical Industry Statistics. Gitnux. https://gitnux.org/pharmacuetical-industry-statistics/#top-companies
report visual · Comparison
Share of the global prescription pharmaceutical market by region, 2023 sales at ex-factory prices
North America holds the largest share at 53.3%.
North America53.3%
Europe22.7%
Africa, Asia and Australia8%
China7.5%
Japan4.3%
Latin America4.2%
source-verifiedefpia.eu
03 Trends & forecasts
Top 10 Pharmacuetical Industry Trends & Forecasts 2027
What is changing in the pharmacuetical industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Global medicine spending keeps expanding
High confidenceThe global prescription pharmaceutical market was estimated at approximately $1.53 trillion in 2024, with the overview forecasting a 5.5–6.5% CAGR through 2029. IQVIA forecasts U.S. net medicine spending to grow 4.5–7.5% annually through 2030, supported by volume growth and new-product adoption.[2]
Forecast 2027: In 2027, global pharmaceutical sales should continue rising at roughly mid-single-digit rates, with emerging-market volume growth and developed-market innovation offsetting patent expiries and pricing pressure.
02Specialty medicines gain market share
High confidenceSpecialty medicines represented 63% of biopharmaceutical blockbusters in 2024, according to IQVIA. Oncology, immunology and diabetes treatments together rose from 5% of blockbusters in 2000 to 60% in 2024.[2]
Forecast 2027: By 2027, specialty products should account for a still larger share of industry revenue, particularly in oncology, immunology, rare diseases, neurology and metabolic disorders.
03Obesity medicines become a major growth engine
High confidenceIQVIA estimates that global obesity-medicine list-price sales reached $66 billion in 2025 and forecasts $92 billion in 2026, with the market potentially reaching $105–200 billion from 2027 onward.[2]
Forecast 2027: In 2027, obesity medicines should remain one of pharma’s fastest-growing categories, with competition shifting toward oral formulations, longer dosing intervals, combination mechanisms, tolerability and broader payer coverage.
04Prescription use grows but access lags
High confidenceU.S. prescription-medicine use reached 210 billion days of therapy in 2025, up 13% over five years, while IQVIA reports that coverage denials and out-of-pocket costs still prevent many patients from obtaining prescribed treatments.[2]
Forecast 2027: In 2027, utilization should continue to increase, but affordability, formulary restrictions and prior authorization will remain important constraints on realized demand, especially for high-cost specialty and obesity therapies.
05Patent expiries widen replacement pressure
High confidenceEY estimates that patent expiries could create approximately $240 billion in growth gaps for the top 25 biopharmaceutical companies by 2030. IQVIA also identifies patent expiries and policy effects as major offsets to medicine-spending growth through 2030.[25][2]
Forecast 2027: By 2027, companies should intensify lifecycle management, launch preparations, licensing and acquisitions to replace revenue at risk from loss of exclusivity, particularly for large biologic franchises.
06Biosimilar competition broadens
High confidenceFDA reported 18 biosimilar approvals in 2024, the highest annual total at that time. FDA’s 2025 approval review stated that 81 biosimilars covering 20 reference products had been approved since 2015, while FDA records show additional approvals in 2026.[60]
Forecast 2027: In 2027, biosimilar launches and interchangeability should increase competition in oncology, immunology, ophthalmology, diabetes and bone disease, producing greater payer leverage and lower net prices for exposed biologics.
07Drug-price pressure intensifies
High confidenceU.S. prescription-drug prices across brands and generics were 2.78 times those in 33 OECD comparison countries in 2022; U.S. brand prices were 4.22 times comparison-country levels. IQVIA expects policy effects and lower-price drivers to restrain U.S. spending growth through 2030.[24][2]
Forecast 2027: In 2027, manufacturers should face stronger pressure from government negotiation, payer contracting, rebates and international price comparisons, although launch prices for differentiated specialty medicines are likely to remain high.
08Novel-drug output remains innovation-led
Medium confidenceFDA’s CDER approved 46 novel drugs in 2025, including 34 new molecular entities and 12 therapeutic biologics. Twenty approvals were first-in-class, and 23 were for rare or orphan diseases.[60]
Forecast 2027: In 2027, annual novel-drug approvals should remain near recent historical highs, with a disproportionate contribution from specialty, rare-disease, oncology, immunology, metabolic and neurologic therapies.
09AI moves deeper into drug development
Medium confidenceEY reports that more than 88% of AI-related biobucks investment is concentrated in R&D, particularly drug-target identification, drug design and clinical-trial patient recruitment. EY also describes AI-enabled workflows that can compress preclinical discovery timelines substantially.[25]
Forecast 2027: By 2027, AI should be standard in target discovery, molecule design, trial recruitment and evidence generation, but its effect on approval rates and total development costs will remain uneven and difficult to quantify.
10China-originated innovation gains influence
High confidenceEY states that China accounted for 34% of alliance investment in 2025, while its 2026 biotech report says 39% of U.S. biobucks flowed to China. IQVIA reports that China-to-international licensing deal value more than doubled between 2024 and 2025.[25][2]
Forecast 2027: In 2027, multinational companies should continue licensing and acquiring China-originated assets, especially in oncology, immunology and cardiometabolic disease, while geopolitical and regulatory screening remains stringent.
04 Statistics
Technology & Innovation
Technology and innovation figures point to broad automation and data platform adoption. In 2024, 12% of pharmaceutical companies’ IT budgets went to pharmacovigilance automation initiatives.
AI in the pharmacuetical industry
- 17.1% of AI-enabled drug-discovery companies were based in the European Union in 2023.[1]
- 3.6% of AI-enabled drug-discovery companies were based in China in 2023.[1]
- 66 new AI-focused partnerships involving large pharmaceutical companies were recorded in 2022.[1]
- 53.3% of AI-enabled drug-discovery companies were based in the United States in 2023.[1]
- 10.0% of AI-enabled drug-discovery companies were based in the United Kingdom in 2023.[1]
- 21 new AI-focused partnerships involving large pharmaceutical companies were recorded in 2017.[1]
Automation in the pharmacuetical industry
- 12% of pharmaceutical companies’ IT budgets were committed to pharmacovigilance automation initiatives in 2024.[2]
- 17% of European pharmaceutical manufacturers reported using a digital twin of their facilities in 2025.[3]
- 79% of European pharmaceutical manufacturers used digital twins for new projects in 2025.[3]
- 68% of European pharmaceutical manufacturers prioritized cybersecurity automation for investment over the next 12 months in 2025.[3]
- 50% of pharmaceutical companies invested $1 million to $5 million in pharmacovigilance automation in 2024.[2]
- 68% of European pharmaceutical manufacturers planned to expand cybersecurity investments in 2025.[3]
Digital Transformation in the pharmaceuticals and biotech sector (sector benchmark)
- 58.1% of global pharmaceutical-industry survey respondents were in the pilots or systematic-ongoing-actions stages of Pharma 4.0 adoption in 2023.[4]
- 15.1% of global pharmaceutical-industry survey respondents reported that Pharma 4.0 digital transformation had not started in 2023.[4]
- 35% of clinical-research organizations surveyed were piloting digital technologies in 2024, up from 29% in 2019.[5]
- 13% of clinical-research organizations surveyed reported a comprehensive AI-driven digital programme in 2024.[5]
- 45% of pharmaceutical companies surveyed were pursuing digitalization as an innovation or technology in 2024.[6]
Technology Adoption in the pharmaceuticals and biotech sector (sector benchmark)
- 59% of global biopharma respondents had adopted artificial intelligence or machine learning in 2023.[7]
- 55% of biopharma AI adopters reported using AI in process development in 2024.[8]
- 70% of global biopharma respondents had adopted an R&D data platform in 2023.[7]
- 37% of small biopharma respondents reported that more than 60% of their R&D laboratory instruments had automated data capture in 2024.[9]
- 63% of global biopharma respondents had adopted robotics and automation in 2023.[7]
Cloud Computing in the pharmaceuticals and biotech sector (sector benchmark)
- 17% of large biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[8]
- 23% of small biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[8]
- 77% of life-sciences commercial IT leaders reported investing primarily in cloud infrastructure in 2024.[10]
- 18% of global biopharma respondents had adopted cloud-based scientific software or SaaS in 2023.[7]
- 49% of biopharma survey respondents reported using cloud computing to facilitate day-to-day work in 2021.[11]
Big Data in the pharmaceuticals and biotech sector (sector benchmark)
05 Statistics
Data & Analytics
Data & analytics output emphasizes data quality limits and AI readiness gaps. Across 116 commercial biopharma leaders in 2025, 96% said their data was not well-structured or AI-ready for scaling.
Business intelligence in the pharmacuetical industry
- 49% of surveyed pharmaceutical medical-affairs professionals used analytics software for insight generation in 2023, globally.[13]
- 58% of surveyed pharmaceutical medical-affairs professionals used a data-visualization product for insight generation in 2023, globally.[13]
- 61% of surveyed pharmaceutical medical-affairs professionals used technology to collect data for generating insights in 2023, globally.[13]
- 41% of surveyed pharmaceutical medical-affairs professionals used proprietary tools or systems to store or share insights in 2023, globally.[13]
- 8% of surveyed pharmaceutical medical-affairs professionals described their insight-generation process as highly automated in 2023, globally.[13]
- 37% of surveyed pharmaceutical medical-affairs professionals used spreadsheets for insight generation in 2023, globally.[13]
Data analytics in the pharmacuetical industry
- 29% of surveyed pharmaceutical supply-chain leaders gathered real-time shipment data on all shipments in 2024, globally.[14]
- 53% of pharmaceutical companies surveyed by PPD were employing artificial intelligence in 2024, including 65% of large companies and 44% of small or midsize companies.[6]
- 21% of pharmaceutical survey respondents identified preclinical and clinical trials as the value-chain component benefiting most from big data in 2024, globally.[15]
- 48% of pharmaceutical companies surveyed by PPD were pursuing big data and analytics in 2024, including 55% of large companies and 43% of small or midsize companies.[6]
- 97% of surveyed pharmaceutical supply-chain leaders gathered real-time shipment data for all or some shipments in 2024, globally.[14]
- 68% of pharmaceutical survey respondents were very or quite confident that big data could transform the industry in 2024, globally.[15]
Data Quality in the pharmaceuticals and biotech sector (sector benchmark)
- Across 125 senior U.S. life-sciences leaders, 81% said accuracy and confidence in data were critical components of AI success in biopharma in 2026.[16]
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 73% reported significant data quality issues in 2025.[16]
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 81% identified data quality as their top data issue for the next 12 months in 2025.[16]
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 96% said their data was not well-structured or AI-ready for scaling in 2025.[16]
- Across 500 pharmaceutical and biotechnology executives globally, 44% said their organization was prepared on data quality and completeness in 2025.[17]
Data Governance in the pharmaceuticals and biotech sector (sector benchmark)
- Across 11 pharmaceutical regulatory organizations, 9% reported a comprehensive approach to onboarding standards such as IDMP and XEVMPD, with regular source qualification, connected systems and data cleaning in 2023.[18]
- Across 500 pharmaceutical and biotechnology executives globally, 54% said their organization was prepared on data governance in 2025.[17]
- Across 200 global life-sciences R&D respondents, 46% called for templates for standardization and metadata to make data FAIR at scale in 2024.[19]
- Across 200 global life-sciences R&D respondents, 51% identified maintenance and management of data standards and ontologies as a key FAIR-data need in 2024.[19]
- Across 200 global life-sciences R&D respondents, 49% called for more data-governance frameworks to make data FAIR at scale in 2024.[19]
KPIs in the pharmacuetical industry
- 55% of surveyed pharmaceutical companies tracked escalation rate as a medical-information KPI in 2024, globally.[20]
- 65% of surveyed pharmaceutical companies tracked the number of documents created or updated as a medical-information KPI in 2024, globally.[20]
- 97% of surveyed pharmaceutical companies tracked inquiry volume as a medical-information KPI in 2024, globally.[20]
- 77% of surveyed pharmaceutical companies tracked response turnaround time as a medical-information KPI in 2024, globally.[20]
- 55% of surveyed pharmaceutical companies tracked question topics or categories as a medical-information KPI in 2024, globally.[20]
- 61% of surveyed pharmaceutical companies distinguished between metrics and KPIs in 2024, globally.[20]
06 Statistics
Strategy & Growth
Strategy & growth highlights specialty and rare-disease pipeline composition alongside pricing and replacement pressure. In 2025 U.S. CDER approvals, 23 products received orphan-drug designation.
Growth in the pharmacuetical industry
- $1,457 billion was the estimated global pharmaceutical market value in 2022.[21]
- $2,100–$2,200 billion is the projected global pharmaceutical market value for 2029.[21]
- 22% of the global pharmaceutical market by value was represented by Asia-Pacific in 2024.[21]
- $1,494 billion was the estimated global pharmaceutical market value in 2023.[21]
- $1,416 billion was the estimated global pharmaceutical market value in 2021.[21]
- 4% of the global pharmaceutical market by value was represented by South America in 2024.[21]
Differentiation in the pharmacuetical industry
- Over one-quarter of specialty medicines in Canada were orphan-designated biologics in 2023.[22]
- 2%–4% of global branded medicines launched each year qualify as blockbusters, according to IQVIA’s 2024 analysis.[2]
- 63% of global branded medicine sales at list prices came from blockbuster medicines in 2024.[2]
- Almost one-quarter of specialty medicines in Canada had biologic, orphan and cancer attributes combined in 2024.[22]
- 52% of new medicines in Canada were biologics in 2022.[22]
- 38% of new medicines in Canada were biologics in 2021.[22]
Mergers and acquisitions in the pharmacuetical industry
- 79 mergers, acquisitions and divestments were announced in the life-sciences sector in the fourth quarter of 2024.[2]
- Oncology was the most frequently targeted therapeutic area in pharmaceutical mergers and acquisitions from 2010 to 2023.[23]
- 5.9% was the average increase in market concentration during the 12 months after a pharmaceutical merger or acquisition.[23]
- 174 pharmaceutical-sector mergers and acquisitions were recorded in 2012, the minimum in the 2010–2023 series.[24]
- 200 pharmaceutical-sector mergers and acquisitions were recorded in 2010, approximately.[23]
- 41% was the decrease in global life-sciences merger-and-acquisition investment from 2023 to 2024.[25]
Strategic partnerships in the pharmacuetical industry
- $1.825 billion was the maximum milestone value in AstraZeneca’s 2024 licensing agreement with Eccogene for the obesity candidate ECC5004.[2]
- 5 billion dollars was the aggregate potential value of U.S. and European biopharma alliances in 2016.[25]
- 8 billion dollars was the aggregate potential value of U.S. and European biopharma alliances in 2014.[25]
- 48 China-related biopharma alliance deals were recorded in 2025.[25]
- 251 strategic alliances were announced by U.S. and European biopharma companies in 2014.[25]
- $6.01 billion was the potential value of Jiangsu Hengrui Pharma’s 2024 licensing agreement with Kailera Therapeutics for three GLP-1 obesity candidates.[2]
07 Statistics
People & Workforce
People & workforce reporting tracks R&D staffing scale and turnover patterns. In 2022, 1.1 million pharmaceutical-industry employees worldwide worked in research and development.
Hiring in the pharmacuetical industry
- 1.1 million pharmaceutical-industry employees worldwide worked in research and development in 2022.[26]
- 1,935 new employees joined Amneal Pharmaceuticals globally in 2024.[27]
- 211,020 pharmaceutical job postings were recorded in the United States in 2021.[28]
- 7.8 million people were directly employed by the global pharmaceutical industry in 2022.[26]
- Global pharmaceutical-industry R&D employment increased 175% from 2014 to 2022.[26]
Employee retention in the pharmacuetical industry
- AstraZeneca reported 10.9% total employee turnover globally in 2024.[29]
- AstraZeneca reported 12.6% total employee turnover globally in 2023.[29]
- AstraZeneca reported 6.1% voluntary employee turnover globally in 2024.[29]
- Novartis reported 7% voluntary employee turnover globally in 2025.[30]
- DSM-Firmenich reported an 83% employee intention-to-stay score globally in 2025.[27]
Remote Work in the pharmaceuticals and biotech sector (sector benchmark)
- Across U.S. life sciences companies, 65.9% reported implementing, expanding, or considering remote-work options for at least some employees in 2023.[31]
- Among life-sciences companies with remote-work options, 50.0% cited competition with technology and other industries as a reason for their policy in 2023.[31]
- Among privately held life-sciences companies surveyed, 21.7% had some portion of their workforce fully remote in 2025.[32]
- Across U.S. chemical and pharmaceutical manufacturers, 5.7% of positions were fully remote in the 2024 hiring outlook survey.[33]
Hybrid Work in the pharmaceuticals and biotech sector (sector benchmark)
- Among life-sciences CEOs, 83% expected corporate employees whose roles were traditionally office-based to work in a hybrid environment three years after the 2024 survey.[34]
- Among surveyed life-sciences employers in the BioHealth Capital Region, 60% expected at least a hybrid workforce after the pandemic in 2021.[35]
- Across U.S. chemical and pharmaceutical manufacturers, 44.5% of positions were fully hybrid in the 2024 hiring outlook survey.[33]
- Among surveyed life-sciences companies in the MassBio Human Resources Roundtable, 97% planned to implement hybrid work models for the long term in 2022.[36]
Upskilling in the pharmacuetical industry
- AstraZeneca invested $108 million in employee upskilling globally in 2024.[29]
- Sun Pharmaceutical spent an average of INR 3,153 per employee on training and development in fiscal 2023–24.[27]
- AstraZeneca employees averaged 34 learning hours globally in 2024.[29]
- 100% of Sanofi employees completed at least one training module globally in 2024.[27]
- Sanofi offered 126,826 training modules globally in 2024.[27]
Employee Engagement in the pharmaceuticals and biotech sector (sector benchmark)
- Across the Culture Amp pharmaceuticals benchmark, 91% of employees agreed they understood how their work contributed to company goals in July 2026.[37]
- At Amneal Pharmaceuticals, global employee engagement reached 88% in the company’s 2024 reporting year.[38]
- Across the Culture Amp pharmaceuticals benchmark, 18% of employees were thinking of or actively seeking another job in July 2026.[37]
- Across the Culture Amp pharmaceuticals benchmark, 17% of employees disagreed that they had seen positive changes based on recent employee survey results in July 2026.[37]
DEI in the pharmacuetical industry
08 Statistics
Customer & Sales
Customer & sales metrics show adoption and adherence outcomes alongside customer-engagement satisfaction. In 2024, 92.3% was the prescription-days-covered adherence rate reported by a specialty pharmacy.
Customer experience in the pharmacuetical industry
- 26% was the highest pharmaceutical-company HCP Net Promoter Score in ZS’s 2025 U.S. survey.[40]
- -57% was the lowest pharmaceutical-company HCP Net Promoter Score in ZS’s 2025 U.S. survey.[40]
- 80% of pharmaceutical executives said they were satisfied with their customer-engagement strategies, compared with 35% of HCPs who said pharma customer-facing resources met their needs, in 2024.[11]
- 49% of pharmaceutical companies said they needed to improve their use of data to provide more personalized experiences in 2024.[41]
- 51% of pharmaceutical companies identified improving user experiences across digital platforms as a key priority in 2024.[41]
Customer retention in the pharmacuetical industry
- 33% of U.S. prescription patients reported at least one medication-adherence issue in 2024.[42]
- 65% of patients acquired through a GoodRx pharmaceutical-brand program converted from a competing therapy in 2024.[43]
- 92.3% was the prescription-days-covered adherence rate reported by a specialty pharmacy in 2024.[44]
- 5% of U.S. prescription patients said they picked up a medicine but did not take any of it in 2024.[42]
- 20% of U.S. prescription patients reported skipping one or more medication doses in 2024.[42]
Customer acquisition in the pharmacuetical industry
- 286% was the lift in new-to-brand prescriptions generated by GoodRx for a pharmaceutical brand in a 2023–2024 test-versus-control study.[43]
- $15.1 million in incremental revenue was generated for a pharmaceutical brand through GoodRx in a 2023–2024 case study.[43]
- 52% of pharmaceutical executives cited providing relevant product, disease and treatment information as a digital-marketing objective in 2025.[45]
- 56% of pharmaceutical executives cited building brand awareness and recognition as a digital-marketing objective in 2025.[45]
- 23% of pharmaceutical executives cited generating leads and converting prescribing physicians as a digital-marketing objective in 2025.[45]
Customer loyalty in the pharmacuetical industry
- 57% of respondent patient groups rated pharmaceutical companies’ corporate reputation positively in 2024.[46]
- 46% of respondent patient groups rated pharmaceutical companies’ integrity as good or excellent in 2024.[46]
- 49% of respondent patient groups rated pharmaceutical companies’ information provision as good or excellent in 2024.[46]
- 29% of respondent patient groups rated pharmaceutical companies’ clinical-data transparency as good or excellent in 2024.[46]
- 30% of respondent patient groups rated pharmaceutical companies’ access-to-medicines performance as good or excellent in 2024.[46]
Lead generation in the pharmacuetical industry
- 23% of pharmaceutical marketing leaders cited generating leads and converting them into prescribing physicians as a digital-marketing objective in 2025.[45]
- 39% of pharmaceutical marketing leaders cited generating leads, delivering educational materials and facilitating HCP communication as a digital-marketing objective in 2025.[45]
- 46% of pharmaceutical marketing leaders cited building strong HCP relationships and engagement as a digital-marketing objective in 2025.[45]
- 17% of pharmaceutical marketing leaders cited protecting or enhancing brand reputation as a digital-marketing objective in 2025.[45]
- 52% of pharmaceutical marketing leaders cited providing relevant product, disease and treatment information as a digital-marketing objective in 2025.[45]
09 Statistics
Marketing & Brand
Marketing & brand metrics connect digital spend and audience behavior to promotion. For 2026, 4.7% was the projected pharmaceutical advertising growth rate.
Marketing in the pharmacuetical industry
- $50 billion was the combined U.S. pharmaceutical television-advertising spend over the decade covered by IQVIA.[2]
- 15.2% was the five-year compound annual growth rate of revenue in WPP Media’s pharmaceutical composite.[47]
- 4.7% was the projected pharmaceutical advertising growth rate for 2026.[47]
- 65.4% of biopharma and medtech marketing-budget respondents reallocated money from sales forces to non-personal tools or sales-representative support.[48]
- 88% was the pharmaceutical sector’s share of total U.S. healthcare-industry digital advertising spending in 2024.[49]
Digital marketing in the pharmacuetical industry
- 35% of pharmaceutical and healthcare advertising professionals identified first-party data mastery as a critical investment in 2024.[50]
- 27% of pharmaceutical and healthcare advertising professionals identified automation as a critical investment in 2024.[50]
- $2.1 million was the average per-brand pharmaceutical spend on paid search in 2018.[51]
- $4.1 million was the average per-brand pharmaceutical spend on banner, display and alert advertising in 2018.[51]
- $600,000 was the average per-brand pharmaceutical spend on email marketing in 2022.[51]
Branding in the pharmacuetical industry
- $6.123 billion was Pfizer’s pharmaceutical brand value in 2024, ranking third globally.[52]
- $5.316 billion was AstraZeneca’s pharmaceutical brand value in 2024.[52]
- $13.361 billion was Johnson & Johnson’s pharmaceutical brand value in 2024, ranking first globally.[52]
- $5.681 billion was Novartis’s pharmaceutical brand value in 2024.[52]
- $4.711 billion was GSK’s pharmaceutical brand value in 2024.[52]
Influencer Marketing in the pharmaceuticals and biotech sector (sector benchmark)
- 10% of healthcare and pharmaceutical marketers said they did not invest in creator or influencer marketing in 2026, globally.[55]
- 50% of healthcare and pharmaceutical marketers reported dedicated and growing budgets for creator or influencer marketing in 2026, globally.[55]
- 29% of healthcare and pharmaceutical marketers reported dedicated but flat budgets for creator or influencer marketing in 2026, globally.[55]
- 4.5% of high-engagement prescription-drug promotion posts across Facebook, Instagram, TikTok and YouTube came from pharmaceutical companies in the United States in 2025.[56]
- 44% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their perception of a medication in 2024.[57]
10 Statistics
Operations & Execution
Operations & execution figures show manufacturing productivity and regulatory/compliance volume. In FY2024 in the United States, 105 quality-related warning letters were issued to human drug manufacturing sites.
Process optimization in the pharmacuetical industry
- 1.0% was the year-over-year labor-productivity decrease in U.S. pharmaceutical and medicine manufacturing in 2019.[58]
- 0.4% was the year-over-year labor-productivity decrease in U.S. pharmaceutical and medicine manufacturing in 2021.[58]
- 2.8% was the year-over-year labor-productivity increase in U.S. pharmaceutical and medicine manufacturing in 2023.[58]
- 3.3% was the year-over-year labor-productivity increase in U.S. pharmaceutical and medicine manufacturing in 2024.[58]
- 1.9% was the year-over-year labor-productivity increase in U.S. pharmaceutical and medicine manufacturing in 2014.[58]
Operational efficiency in the pharmacuetical industry
- 2.4% was the productivity increase in U.S. pharmaceutical and medicine manufacturing in 2024.[59]
- 369,500 jobs are projected for U.S. pharmaceutical and medicine manufacturing in 2034.[59]
- 6,640 biochemists and biophysicists were employed in U.S. pharmaceutical and medicine manufacturing in May 2024.[59]
- 6,880 industrial production managers were employed in U.S. pharmaceutical and medicine manufacturing in May 2024.[59]
- 30,510 chemical equipment operators were employed in U.S. pharmaceutical and medicine manufacturing in May 2024.[59]
Quality management in the pharmacuetical industry
- 15 manufacturers accounted for 94% of 407 recalled store-branded OTC products during FY2020–FY2024 in the United States.[60]
- 105 quality-related warning letters were issued to human drug manufacturing sites in FY2024 in the United States.[60]
- 30 pharmaceutical product recalls were attributed to labeling problems in FY2024 in the United States.[60]
- 17 pharmaceutical product recalls were attributed to packaging problems in FY2024 in the United States.[60]
- 0.23% of top-100 OTC store-brand products were recalled in FY2024 in the United States.[60]
Supply chain in the pharmacuetical industry
- 11.6% was the growth in traditional pharmaceutical distributor sales in 2025 in the United States.[61]
- 88% of unfilled pharmaceutical invoice lines were attributed to manufacturers’ inability to ship in 2025 in the United States.[61]
- $55 billion was the approximate pharmaceutical inventory held daily by U.S. distributors in 2025.[61]
- 102 active drug shortages were reported by FDA as of June 2024 in the United States.[2]
- $969 billion in pharmaceutical distributor sales were recorded in 2025 in the United States.[61]
Outsourcing / Offshoring in the pharmaceuticals and biotech sector (sector benchmark)
- 54% of global biotech and pharma companies outsourced regulatory activities in 2024, according to an IQVIA industry report.[2]
- 67% of global biotech and pharma companies outsourced pharmacovigilance operations in 2024, according to an IQVIA industry report.[2]
- 12% of total API volume used in the United States was produced domestically in 2024, with most supply coming from India and the European Union.[62]
- 40% of surveyed pharma and biotech CDMO decision-makers identified small-molecule API as the most outsourced product in July 2024.[63]
- 41% of surveyed pharmaceutical and biotech R&D leaders increased their use of functional-service-provider outsourcing versus two years earlier in 2023.[6]
11 Statistics
Finance & Pricing
Finance & pricing figures stress price-cost pressure and R&D intensity. In 2024, large-pharma R&D expenditure was 25.2% of sales.
Pricing strategy in the pharmacuetical industry
- $716 billion was U.S. prescription-drug sales in 2022, up 23% from $582 billion in 2017.[24]
- 5.0% of the average European retail price of a medicine went to wholesalers in 2023.[64]
- $1.529 trillion was the value of the global prescription-pharmaceutical market at ex-factory prices in 2024.[64]
- 10.5% of the average European retail price of a medicine represented VAT and other state taxes in 2023.[64]
- 2.3% was the average list-price increase for medicines in 2024, while net prices rose 0.1% and inflation-adjusted net prices fell 3%.[65]
Cost reduction in the pharmacuetical industry
- $4.5 billion was Pfizer’s increased overall net-savings target for the end of 2025.[66]
- €2 billion was Sanofi’s targeted savings from 2024 through the end of 2025.[67]
- $1.5 billion was Novartis’s revised estimated annual saving from SG&A simplification and operations synergies, fully embedded by 2024.[68]
- $4 billion in net cost savings was delivered by Pfizer’s cost-realignment program by the end of 2024.[66]
- €2.7 billion was Sanofi’s announced cost-savings plan in 2023 to reinvest in growth drivers.[67]
Profitability in the pharmacuetical industry
Financial planning in the pharmacuetical industry
- 20.4% was large-pharma R&D expenditure as a percentage of sales in 2020.[69]
- 25.2% was large-pharma R&D expenditure as a percentage of sales in 2024.[69]
- $136 billion was large-pharma R&D expenditure in 2021.[69]
- 19.3% was large-pharma R&D expenditure as a percentage of sales in 2021.[69]
- $163 billion was large-pharma R&D expenditure in 2023.[69]
12 Statistics
Product & Service
Product & service reporting connects clinical-development throughput with patient support allocation. In 2024, 5,318 clinical trials were started worldwide.
Product development in the pharmacuetical industry
- 5,318 clinical trials were started worldwide in 2024, according to IQVIA’s pharmaceutical R&D analysis.[69]
- 7.7% of PhRMA member companies’ R&D spending went to Phase IV research in 2024, United States.[70]
- 43% of product-indication pairs in active development worldwide focused on cancer in 2023.[71]
- $104.344 billion was spent on company-financed R&D by PhRMA member companies in 2024, including preclinical, clinical, approval and post-approval research, United States.[70]
- 27.4% of PhRMA member companies’ R&D spending went to Phase III development in 2024, United States.[70]
Product lifecycle in the pharmacuetical industry
- 113 low- and middle-income countries were included in the 2024 Access to Medicine Index analysis of pharmaceutical product access.[72]
- 48 novel drugs were approved by FDA CDER in the United States in 2019.[60]
- 22 novel drugs were approved by FDA CDER in the United States in 2016, the lowest annual total from 2015 through 2024.[60]
- 24 of the 50 novel drugs approved by FDA CDER in 2024 were classified as first-in-class, equal to 48%.[60]
- 20 leading pharmaceutical companies were assessed in the 2024 Access to Medicine Index across product delivery, R&D and access governance.[72]
After-sales in the pharmacuetical industry
- Pharmaceutical companies invest more than $5 billion annually in patient support programs, according to IQVIA.[2]
- 3% of patients engage with pharmaceutical patient support programs, according to IQVIA’s analysis.[2]
- 72% of surveyed health-system specialty pharmacies cited identifying patients needing pharmacist intervention as a reason for reporting disease-state-specific outcomes in 2024, United States.[73]
- 46% of patients remained on therapy after two years in one pharmaceutical-sponsored patient support program, compared with 34% in the control group.[2]
- 4% to 12% of annual revenue is allocated to patient support programs by large pharmaceutical companies, according to IQVIA.[2]
Value proposition in the pharmacuetical industry
- Sanofi ranked third among 20 pharmaceutical companies in the 2024 Access to Medicine Index.[72]
- 54.0% of 2024 AMCP Foundation survey respondents considered a 50% increase in pharmaceutical value-based-contract adoption somewhat or highly likely.[74]
- 3 technical areas—governance of access, research and development, and product delivery—structured the 2024 Access to Medicine Index.[72]
- 60% to 75% of 2024 revenue came from the United States for AbbVie, Gilead, Bristol Myers Squibb, Amgen, Eli Lilly and Pfizer, according to a report cited by Le Monde.[75]
- 113 low- and middle-income countries were covered by the 2024 Index’s assessment of pharmaceutical access performance.[72]
13 Statistics
Sustainability & Ethics
Sustainability & ethics figures link environmental targets to access programs. AstraZeneca reached more than 90 million people through flagship access programmes by end of 2024.
Sustainability in the pharmacuetical industry
- 23% reduction in water use was achieved by AstraZeneca in 2024 versus its 2015 baseline, globally.[76]
- 87% of AstraZeneca product-sales revenue came from brands with completed life-cycle assessments in 2024.[76]
- More than 156,000 people had been trained cumulatively through AstraZeneca programmes since 2015 by the end of 2024.[76]
- 71% of AstraZeneca product-sales revenue came from brands scored against its Product Sustainability Index in 2024.[76]
- More than 90 million people were reached through AstraZeneca’s flagship access programmes by the end of 2024.[76]
ESG in the pharmacuetical industry
- 5th place was shared by AstraZeneca and Johnson & Johnson in the 2024 Access to Medicine Index ranking.[72]
- 1st place was achieved by Novartis in the 2024 Access to Medicine Index ranking of 20 pharmaceutical companies.[72]
- 308 pharmaceutical firms disclosed an ESG sustainability profile at least once in 2024 in a study of pharmaceutical-firm reporting.[77]
- 86 European pharmaceutical and biotechnology companies were assessed in EthiFinance’s 2024 ESG performance analysis using fiscal-year 2023 data.[78]
- 3rd place was achieved by Sanofi in the 2024 Access to Medicine Index ranking of 20 pharmaceutical companies.[72]
Ethics in the pharmacuetical industry
- 20 pharmaceutical companies were assessed for third-party compliance systems in the 2024 Access to Medicine Index.[72]
- 20 pharmaceutical companies were assessed for country- or region-based risk assessments in the 2024 Access to Medicine Index.[72]
- 20 pharmaceutical companies were evaluated for fraud, corrupt-practice and clinical-trial-misconduct controls in the 2024 Access to Medicine Index.[72]
- 20 pharmaceutical companies were assessed for fraud-specific risk assessments in the 2024 Access to Medicine Index.[72]
- 1% to 3% of FDA inspections per year involved scientific misconduct, according to FDA regulatory-review evidence covering clinical research oversight.[24]
CSR in the pharmacuetical industry
- 3 technical areas were used to assess pharmaceutical CSR-related access efforts in 2024: governance of access, research and development, and product delivery.[72]
- 20 pharmaceutical companies were ranked in the 2024 Access to Medicine Index for efforts to improve access to medicines in low- and middle-income countries.[72]
- 80% of participating pharmacies achieved a 4-out-of-5 stock-management quality grade in Sanofi’s Tanzania initiative by 2025.[79]
- 113 low- and middle-income countries were included in the 2024 pharmaceutical access assessment.[72]
- 32 metrics were used to evaluate pharmaceutical-company access performance in the 2024 Access to Medicine Index.[72]
Circular economy in the pharmacuetical industry
- 2.5 tonnes of research equipment were reused by Chugai in 2024.[80]
- 41% of AstraZeneca’s total waste was recycled in 2024, globally.[76]
- 504 tonnes of materials were recycled by Chugai in 2024, including plastics, metals, waste oil and other materials.[80]
- 1.1 thousand tonnes of Novartis operational waste were landfilled in 2025.[81]
- 6,029 tonnes of external waste were avoided through reuse and by-products at AstraZeneca in 2024.[76]
Carbon footprint in the pharmacuetical industry
- 55.6 thousand tonnes of Novartis Scope 3 emissions came from investments in 2025.[81]
- 3,246.7 thousand tonnes of Novartis Scope 3 emissions came from purchased goods and services in 2025.[81]
- 138 million tonnes of carbon-dioxide equivalent came from private biotechnology and pharmaceutical companies in 2023.[82]
- 126.9 thousand tonnes of Novartis Scope 3 emissions came from business travel in 2025.[81]
- 204.4 thousand tonnes of Novartis Scope 1 and 2 greenhouse-gas emissions from energy were reported in 2025.[81]
14 Statistics
Risk, Compliance & Legal
Risk, compliance & legal figures emphasize cybersecurity incidence and privacy constraints. In the Fortinet 2021 survey, 98% of surveyed pharmaceutical firms experienced at least one cybersecurity intrusion in the prior 12 months.
Compliance in the pharmacuetical industry
- 85 regulatory meetings with pharmaceutical companies were held by FDA’s Office of Compliance in 2025 in the United States.[60]
- 970 drug-manufacturing inspection classification letters were issued by FDA in 2025 in the United States.[60]
- 9 centrally authorised medicines were subject to batch recalls following confirmed quality defects reported to the European Medicines Agency in 2024.[83]
- 10,922 drug listings were inactivated from FDA’s Drug Registration and Listing System in 2025 in the United States.[60]
- 409 inspection and compliance documents were shared with foreign regulatory counterparts by FDA in 2025.[60]
Risk Management in the pharmaceuticals and biotech sector (sector benchmark)
- 85% of global life science firms had a formal business continuity process covering the whole business in 2024.[84]
- 52% of middle-market life sciences companies reported having a business continuity plan in place.[85]
- 81% of middle-market life sciences companies said risk management was a top priority, rising to 90% among the fastest-growing organizations.[85]
- 90% of clinical trials managed by surveyed CROs included at least one risk-based monitoring or risk-based quality-management component in 2025.[86]
- 44% of global life science firms reported no standardized or consistently effective intellectual-property risk-management process in 2024.[84]
Cybersecurity in the pharmaceuticals and biotech sector (sector benchmark)
- 52% of surveyed middle-market life sciences companies reported experiencing a cybersecurity breach.[85]
- 98% of surveyed pharmaceutical firms experienced at least one cybersecurity intrusion in the 12 months covered by Fortinet’s 2021 survey.[87]
- 27% of healthcare, biotechnology, and pharmaceutical respondents had little or no confidence in identifying where their data was stored in 2025.[88]
- 40% of surveyed pharmaceutical businesses experienced outages affecting productivity, safety, compliance, revenue, or brand image.[87]
- 28% of surveyed pharmaceutical businesses lost business-critical data or intellectual property because of cybersecurity incidents.[87]
Data Privacy in the pharmaceuticals and biotech sector (sector benchmark)
- 66% of pharma, biotech, and medical-device respondents said patient privacy presented a challenge when complying with journal data-sharing policies in 2024.[89]
- 61% of surveyed pharmaceuticals and life sciences organizations identified GDPR as a top-two privacy and compliance focus in 2024.[90]
- 39% of surveyed pharmaceuticals and life sciences organizations said they tagged and classified around three-quarters of their unstructured data in 2024.[90]
- Stricter privacy regulation was associated with an approximately 39% reduction in R&D spending by global pharmaceutical and biotechnology firms four years after implementation.[91]
- 84% of surveyed pharmaceuticals and life sciences organizations said measuring and managing sensitive-content compliance required some to significant improvement in 2024.[90]
Crisis Management in the pharmaceuticals and biotech sector (sector benchmark)
- 50% of surveyed global life science firms identified logistics and warehousing shortages as a major supply-chain risk for the following two years.[84]
- 52% of surveyed global life science firms identified contract-manufacturing issues as a major supply-chain risk for the following two years.[84]
- 40% of surveyed pharmaceutical firms maintained inventory buffers of one to three months to protect against supply-chain disruption.[92]
- 48% of surveyed global life science firms identified natural disasters as a major supply-chain risk for the following two years.[84]
- 61% of surveyed global life science firms identified panic buying and stockpiling as a major supply-chain risk for the following two years.[84]
Governance in the pharmacuetical industry
- 61% of products assessed lacked access strategies in low-income countries in the 2024 Access to Medicine Index.[72]
- 50% of Novo Nordisk’s 12-member Board of Directors were women as of December 31, 2024.[66]
- 113 low- and middle-income countries were covered by the 2024 Access to Medicine Index’s pharmaceutical-company assessment.[72]
- 93 new priority R&D projects were added by assessed pharmaceutical companies in the 2024 Index period, versus 151 previously.[72]
- 20 leading pharmaceutical companies were assessed in the 2024 Access to Medicine Index across governance, R&D and product-delivery metrics.[72]
15 Statistics
Globalization & Expansion
Globalization & expansion highlights cross-border market activity and API sourcing geography. As of October 23, 2026, 84 FDA-registered API manufacturing sites were located in Japan.
Globalization in the pharmacuetical industry
- $103.9 billion of pharmaceutical R&D expenditure occurred in the United States in 2022.[71]
- 15.8% of sales of new medicines launched during 2018–2023 occurred in Europe’s five largest markets.[93]
- 7.0% of global pharmaceutical sales came from China in 2024, based on estimated sales of $159.9 billion.[66]
- $927 billion in pharmaceutical trade was recorded globally in 2022.[94]
- $222.0 billion in pharmaceutical sales were recorded across Southeast and East Asia in 2024.[66]
Cultural adaptation in the pharmacuetical industry
- 298 pharmaceutical clinical trials were conducted in Japan in 2023, representing 7% of the global total in the EFPIA comparison.[95]
- 179 pharmaceutical clinical trials were conducted in South Korea in 2023, representing 4% of the global total in the EFPIA comparison.[95]
- 74 pharmaceutical clinical trials were conducted in the United Kingdom in 2023, representing 2% of the global total in the EFPIA comparison.[95]
- 50 novel drugs approved in the United States in 2024 were covered by FDA Drug Trials Snapshots demographic reporting.[96]
- 131 pharmaceutical clinical trials were conducted in Iran in 2023, representing 3% of the global total in the EFPIA comparison.[95]
Supplier management in the pharmacuetical industry
- 84 FDA-registered API manufacturing sites were located in Japan as of October 23, 2026.[97]
- 72% of API manufacturing sites receiving FDA regulatory actions over the previous five years exclusively supplied compounding pharmacies.[60]
- 57 FDA-registered API manufacturing sites were located in Spain as of October 23, 2026.[97]
- 51% of violative API manufacturing sites supplying only compounding pharmacies were located in China.[60]
- 85 FDA-registered API manufacturing sites were located in Germany as of October 23, 2026.[97]
Stakeholder management in the pharmacuetical industry
- 35 countries were represented in PatientView’s 2025–2026 survey of patient-group perceptions of pharmaceutical companies.[98]
- 28% of U.S. consumers viewed the pharmaceutical industry very or somewhat positively in Gallup’s 2025 reputation survey.[49]
- Around half of surveyed UK healthcare professionals considered government or regulators reliable sources of pharmaceutical-sector information in 2026.[99]
- 61% of patient groups responding to PatientView’s 2017 survey reported a working relationship with at least one pharmaceutical company.[46]
- 67% of surveyed pharmaceutical stakeholders identified peer-reviewed medical journals as a company-engagement channel in Deloitte’s 2024 research.[11]
Distribution channels in the pharmacuetical industry
- 42.3% of U.S. pharmaceutical distributor sales came from chain sales in 2023.[61]
- 13.1% of U.S. pharmaceutical distributor sales came from independent drug stores in 2023.[61]
- 95% of U.S. retail pharmaceutical sales passed through wholesalers in 2022.[70]
- 12.5% of U.S. pharmaceutical distributor sales came from mail order in 2023.[61]
- 20.4% of U.S. pharmaceutical distribution-industry sales went to hospitals, HMOs and clinics in 2023.[61]
Key questions about the pharmacuetical industry
What is the size of the global prescription pharmaceutical market?
The global prescription pharmaceutical market was $1.53 trillion in 2024 at ex-factory prices, with an estimated €1.414 trillion at ex-factory prices. A separate Crisil Intelligence estimate placed the broader global pharmaceutical market at $1.583 trillion in 2024.
How fast is the prescription pharmaceutical market expected to grow?
Crisil Intelligence forecasts the global pharmaceutical market to reach $2.1–$2.2 trillion by 2029. That implies a 5.5–6.5% CAGR from 2024 to 2029.
Which companies lead the pharmacuetical industry?
Eli Lilly and Company leads Gitnux's 2026 pharmacuetical ranking with an Overall score of 9.7, with revenue growth 44.7%, operating margin 40.4%, and R&D 20.5% of revenue. Roche is the highest-ranked pharmaceutical and diagnostics company at 9.1, with R&D at 19.8% of revenue and revenue growth 7%.
What technology shifts are most emphasized for 2026 in pharma?
Current outlooks for 2026 emphasize AI-enabled discovery, pipeline replacement, and specialty medicines. In the data set, 58.1% of respondents were in pilots or systematic-ongoing Pharma 4.0 adoption stages in 2023.
How concentrated is the market geographically?
North America and Europe accounted for 77.5% of global prescription pharmaceutical sales in 2024. In 2024, North America represented 54.8% of global prescription sales and Europe represented 22.7%.
What regulatory throughput and approval volumes define recent FDA activity?
FDA CDER approved 46 novel drugs in 2025, including 34 new molecular entities and 12 biologics. FDA also approved 18 biosimilars in 2025.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, November 10). Pharmacuetical Industry Statistics. Gitnux. https://gitnux.org/pharmacuetical-industry-statistics
MLA
Samuel Norberg. "Pharmacuetical Industry Statistics." Gitnux, 10 Nov 2026, https://gitnux.org/pharmacuetical-industry-statistics.
Chicago
Samuel Norberg. 2026. "Pharmacuetical Industry Statistics." Gitnux. https://gitnux.org/pharmacuetical-industry-statistics.
Sources & references
109 sources cited across this report
www2.itif.org
iqvia.com
hexagon.com
ispe.org
pmlive.com
ppd.com
- techresearchinfo.com
test.benchling.com
insights.indegene.com
deloitte.com
pharmamanufacturing.com
- within3.com
eco-cdn.iqpc.com
globaldata.com
veeva.com
capgemini.com
pistoiaalliance.org
link.springer.com
- sebi.gov.in
canada.ca
aspe.hhs.gov
ncbi.nlm.nih.gov
ey.com
ifpma.org
- financialfilings.com
- ohiolifesciences.org
marketscreener.com
novartis.com
- innovatebio.org
- jthelander.com
naceweb.org
assets.kpmg.com
- biobuzz.io
massbio.org
cultureamp.com
- amneal.com
- abbviecontractmfg.com
zs.com
emjreviews.com
ipsos.com
assets.ctfassets.net
advisory.com
epocrates.com
- patient-view.com
wpp.com
marketingcharts.com
emarketer.com
s3.amazonaws.com
mediapost.com
brandirectory.com
- elsmediakits.com
norc.org
- brand-news.it
jamanetwork.com
sermo.com
fred.stlouisfed.org
bls.gov
fda.gov
hda.org
richmondfed.org
glginsights.com
lif.dk
assets.contentstack.io
sec.gov
sanofi.com
- makingpharmaindustry.it
- cdn.aglty.io
oecd.org
- accesstomedicinefoundation.org
doi.org
lemonde.fr
astrazeneca.com
onlinelibrary.wiley.com
ethifinance.com
chugai-pharm.co.jp
mygreenlab.org
ema.europa.eu
- lifesciencesny.org
middlemarketcenter.org
acrohealth.org
fortinet.com
cpl.thalesgroup.com
- openpharma.blog
kiteworks.com
etla.fi
- insights.economistenterprise.com
efpia.eu
documents1.worldbank.org
- medkurier.pl
content.govdelivery.com
- pharmatek.co.uk
statnews.com
abpi.org.uk
pharma.fcio.at
rand.org
lilly.com
roche.com
annualreport.novonordisk.com
jnj.com
merck.com
annualreview.pfizer.com
amgen.com
Social media in the pharmacuetical industry